FDA Fast Tracks Remedy Pharmaceuticals’ CIRARA

Remedy Pharmaceuticals has snagged FDA fast track designation for Cirara for the treatment of large hemispheric infarctions.

Cirara inhibits Sur1-Trpm4 channels, which can lead to edema, midline shift, increased intracranial pressure and brain herniation.

The company plans to initiate a Phase 3 study evaluating the candidate by the end of the year.